Actively Recruiting
Zoledronic Acid Injection to Prevent Bone Loss in Adults Newly Diagnosed with HIV Starting Antiviral Treatment
Led by Hadassah Medical Organization · Updated on 2025-09-18
110
Participants Needed
3
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether a single dose of zoledronic acid can prevent bone mass loss in people newly diagnosed with HIV who are starting antiviral treatment. They aim to understand if bone deterioration occurs despite current HIV medications and whether zoledronic acid can offer protection. This study is a prospective, multicenter, open-label, randomized control trial led by Hadassah Medical Organization. Participants will be divided based on their bone density scores. Those with moderate bone loss T score from -1 to -2.4 will receive one intravenous dose of 5 mg zoledronic acid within a month of starting antiviral therapy, while others with similar scores will be monitored without intervention. Participants with normal bone density T score above -1 will be followed without treatment, and those with severe osteoporosis T score below -2.5 will receive standard care with oral bisphosphonates but will continue follow-up in the study. Blood samples and DXA scans will be collected periodically up to 48 months. Participants will provide blood samples before starting antiviral treatment and at 6, 12, 24, and 48 months to measure bone markers. They will also undergo DXA scans soon after treatment begins and at 12, 24, and 48 months to assess bone density changes. Researchers will monitor bone fractures and track bone density over time. The primary outcome is bone density at 12 months after starting antiviral therapy, with additional measurements continuing for up to four years. This long-term follow-up will help evaluate the protective effect of zoledronic acid against bone loss.
CONDITIONS
Brief Title
Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals
Research Team
H
Hila Doctor Elinav, Doctor
A
Auryan Szalat, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here